Dr. Reddy's Laboratories Limited filings document its U.S. reporting as a foreign private issuer with American depositary receipts listed on the New York Stock Exchange. Recent Form 6-K reports furnish exchange intimations and exhibits submitted to Indian exchanges and the NYSE, including board-meeting notices and other current-report disclosures.
The filing record centers on Rule 13a-16 and 15d-16 submissions, Form 20-F reporting status, governance communications, and public-company notices tied to Dr. Reddy's pharmaceutical operations and securities across India and the United States.
Dr. Reddy’s Laboratories Limited submitted a Form 6-K providing an intimation to multiple stock exchanges about shareholder communications. The company enclosed copies of newspaper advertisements titled “Notice of the 42nd Annual General Meeting to be held through video conference, record date and final dividend information,” published in Business Standard and Nava Telangana. The same communication was also emailed to all shareholders, ensuring broad circulation of details about the upcoming annual general meeting and related dividend information.
Dr. Reddy’s Laboratories Limited reported a routine employee stock option exercise. The company allotted 6,730 equity shares of Re.1 each on June 19, 2026 to eligible employees under its 2002 Employee Stock Option Scheme and 2007 Employees ADR Stock Option Scheme.
The allotment covers 2,455 shares at an exercise price of Re.1, 2,000 shares at Rs. 562.80, and 2,275 shares at Rs. 735.80. After this issue, total issued shares are 83,46,76,800 and total issued share capital is Rs. 83,46,76,800, with paid-up capital of 83,46,75,800 equity shares of Re.1 each.
Dr. Reddy’s Laboratories has announced the first-to-market U.S. launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, expanding its oncology portfolio and focus on affordable cancer care. The product is a first-to-file generic and is eligible for 180 days of generic drug exclusivity for the 400mg strength in the United States.
Dr. Reddy’s holds exclusive marketing rights in the U.S., while MSN Laboratories developed and manufactures the product. The Bosulif 400mg brand recorded approximately $253.8 million in U.S. sales for the 12 months ended April 2026, highlighting the commercial potential of this oncology therapy launch.
Dr. Reddy’s Laboratories Limited filed a Form 6-K to share its schedule of analyst and institutional investor meetings. The company’s management plans to participate in an Investec investor conference in London from June 16, 2026 to June 17, 2026, with in-person group meetings scheduled between 09:00 and 17:00 BST. The company notes that this schedule may change depending on circumstances for either the investors or the company.
Dr. Reddy’s Laboratories Limited reported the allotment of 12,100 equity shares of Re.1 each on June 5, 2026 to eligible employees who exercised stock options. The shares were issued under the Dr. Reddy’s Employees Stock Option Scheme, 2002 and the Employees ADR Stock Option Scheme, 2007.
After this issue, total issued shares stand at 83,46,70,070 and total issued share capital is Rs. 83,46,70,070. The new shares carry no premium, rank pari passu with existing equity shares, and are of the same ISIN INE089A01031.
Dr. Reddy’s Laboratories Limited filed a Form 6-K to inform markets that its management will participate in upcoming investor conferences. The company plans a group investor meet organized by ICICI Securities in Mumbai on June 9, 2026 from 10:00 to 17:00 IST, and another group meeting organized by Macquarie in Hyderabad on June 10, 2026 from 12:00 to 13:00 IST. The company notes that these schedules may change due to exigencies on the part of investors or the company.
Dr. Reddy’s Laboratories Limited has notified exchanges that its management will participate in an investor conference. The meeting is scheduled for June 5, 2026, organized by Bank of America in Hyderabad as an in-person group meeting from 08:00 to 09:00 IST. The company notes that this schedule may change if needed by either the investors or the company. This update is provided as an information-only disclosure on the company’s investor relations activities.
Dr. Reddy’s Laboratories Limited has submitted a Form 6-K to notify investors that it filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2026 with the U.S. Securities and Exchange Commission. The report contains annual consolidated financial statements prepared under International Financial Reporting Standards as issued by the International Accounting Standards Board. The Form 20-F is also available on the company’s website for public access.
Dr. Reddy’s Laboratories has filed its annual Form 20-F for the fiscal year ended March 31, 2026, prepared under IFRS as issued by the IASB. The company reports 834,656,970 equity shares outstanding at period end and American depositary shares listed on the NYSE under the symbol RDY.
The report outlines extensive risk factors, including dependence on successful development, approval and commercialization of generics, complex molecules and biosimilars, as well as stringent global regulatory oversight. It highlights geopolitical disruptions, particularly in Russia, Ukraine and the Middle East, supply-chain and manufacturing quality risks, cyber and data protection threats, evolving drug-pricing and reimbursement regimes in key markets, environmental and sustainability obligations, significant patent and product-liability exposure, tax and foreign-exchange uncertainties, and India-specific corporate, securities and labor law developments.
Dr. Reddy’s Laboratories Limited has furnished a Form 6-K providing its Annual Secretarial Compliance Report for the year ended March 31, 2026, under Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Independent practicing company secretaries examined the company’s records, stock exchange filings, website disclosures and applicable SEBI and listing regulations. They reported that the company complied with all examined SEBI regulations and related circulars and guidelines, with no deviations, fines or violations recorded during the review period.
The report notes that required SEBI-related policies are adopted and updated on time, the company maintains a functional website with accurate links, its directors are not disqualified, performance evaluations are conducted, related party transactions receive prior audit committee approval, and there were no SEBI or stock exchange actions or additional non-compliances during the year.